• 1
    Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92: 276284.
  • 2
    Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer. 2004; 102: 100108.
  • 3
    Bibbo M, DeCecco J, Kovatich AJ. P16INK4A as an adjunct test in liquid-based cytology. Anal Quant Cytol Histol. 2003; 25: 811.
  • 4
    Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol. 2002; 46: 2529.
  • 5
    Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol. 2003; 56: 5663.
  • 6
    Trunk MJ, Dallenbach-Hellweg G, Ridder R, et al. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol. 2004; 48: 771782.
  • 7
    Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol. 2002; 27: 365370.
  • 8
    Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004; 445: 616620.
  • 9
    Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003; 31: 3540.
  • 10
    Cecchini S, Iossa A, Bonardi R, Ciatto S, Cariaggi P. Comparing two modalities of management of women with cytologic evidence of squamous or glandular atypia: early repeat cytology or colposcopy. Tumori. 1997; 83: 732734.
  • 11
    Carozzi FM, Confortini M, Cecchini S, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer Cytopathol. 2005; 105: 27.
  • 12
    Carozzi F, Ronco G, Confortini M, et al. Prediction of high grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer. 2000; 83: 14621467.
  • 13
    Carozzi F, Lombardi FC, Zendron P, et al. Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers. 2004; 19: 257261
  • 14
    Manos MM, Kinney WK, Hurley LB, et al. Identifyng women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999; 281: 16051610.
  • 15
    Solomon D, Schiffman M, Tarone B; ALTS study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293299.
  • 16
    Ferris DG, Litaker MS; ASCUS/LSIL Triage Study (ALTS) Group. Colposcopy quality control by remote review of digitized colposcopic images. Am J Obstet Gynecol. 2004; 191: 19341941.
  • 17
    Hu L, Guo M, He Z, Thornton J, McDaniel LS, Hughson MD. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol. 2005; 18: 267273.
  • 18
    Carozzi F, Confortini M, Cecchini S, Ciatto S. HPV testing for cervical neoplasia. Acta Cytol. 2001; 45: 659661.